Revenue: 1.4 billion Danish Krona, representing a 62% growth compared to the previous year. EBITDA Margin: 31%. Public Preparedness Revenue Growth: 83% increase compared to the prior year. Travel Health Revenue Growth: 52% increase over the prior year. Rabies Vaccine Growth: 53% increase. TBE Vaccine Growth: 62% increase. Gross Margin: 51%, a 2% point improvement from the previous year. R&D Costs: Slightly lower than last year, with a full-year guidance of approximately 900 million Danish Krona. SG&A Costs: Increased from 209 million to 250 million Danish Krona. Cash and Cash Equivalents: Approximately 1.2 billion Danish Krona. Full-Year Revenue Guidance: Between 5.7 and 6.7 billion Danish Krona. Full-Year EBITDA Margin Guidance: Between 26% and 30%.

Release Date: May 09, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Bavarian Nordic AS (BVNKF) reported a strong start to the year with a 62% growth in revenue, reaching almost 1.4 billion krona. The company achieved an EBITDA margin of 31%, indicating strong profitability. Successful launch and approval of the chikungunya vaccine, Bunya, in the US, Europe, and the UK. Strong performance in the travel health segment, with significant market share gains in rabies and tick-borne encephalitis (TBE) vaccines. Secured a new order from the US government worth $144 million, enhancing revenue stability for 2026.

Negative Points

The company is slightly short of the bottom end of the guidance for public preparedness, despite strong performance. Concerns about potential negative impacts from wholesaler stocking in Germany, which could affect future sales. The company faces uncertainties related to potential tariffs and changes in US regulatory policies. There is a cautious approach to travel health growth projections, despite strong Q1 performance, due to seasonality and market dynamics. The company has not yet sold its priority review voucher, indicating potential delays in realizing cash from this asset.

Q & A Highlights

Q: Can you explain the factors contributing to the strong EBITDA margin of 31% this quarter, and how does it align with your full-year guidance of 26% to 30%? A: Henrik Juuel, Executive Vice President and CFO, explained that the strong EBITDA margin was due to a smooth quarter in manufacturing, with better yields and higher success rates. The R&D costs are back-end loaded, which also contributed to the margin. The company remains cautious and maintains its full-year guidance of 26% to 30%, acknowledging that the first quarter's performance is close to the upper end of this range.

Story Continues

Q: What is the outlook for travel health growth for the year, given the strong performance in Q1? A: Henrik Juuel noted that while Q1 showed strong growth, the company is taking a cautious approach due to the seasonal nature of vaccines. There are no current supply constraints, and the company wants to observe a few more months before revisiting full-year expectations. The 2.5 billion target for the year remains, reflecting a cautious stance despite the strong start.

Q: Regarding the chikungunya vaccine, Vinconia, how is the initial feedback, and are there opportunities to capture market share from competitors facing safety concerns? A: Paul Chaplin, President and CEO, acknowledged safety issues with a competitor's product, leading to its suspension for people 65 and older. Bavarian Nordic is in dialogue with French authorities and plans to launch Vinconia in Europe soon. While not changing the guidance for this year, Chaplin noted that increasing chikungunya cases globally could positively impact sales.

Q: Have there been any changes in your strategy or interactions with US organizations, particularly concerning tariffs and FDA regulations? A: Paul Chaplin stated that interactions with the US government, particularly Barda, remain business as usual. There have been no changes in FDA policies affecting their pipeline. Regarding tariffs, the company is preparing for potential scenarios but does not expect significant impact due to some manufacturing already being in the US.

Q: Can you provide an update on the priority review voucher (PRV) and its potential sale? A: Henrik Juuel confirmed that the PRV has not been sold yet, as the company is not in a rush and wants to ensure it is sold at the right price. There is interest from potential buyers, and the company will proceed with the sale when a suitable offer is made.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments